Martin J. Cannon

Federal Grant PI High Impact

Professor

UAMS

Last publication 2026 Last refreshed 2026-05-22

faculty

mjcannon@uams.edu

44 h-index 158 pubs 5,905 cited

Research Areas

Links

ORCID Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Martin J. Cannon's research focuses on the development and application of oncolytic virotherapy and immunotherapy for cancer treatment. He has investigated the potential of various viruses, including Myxoma virus and Morreton virus, as platforms for cancer therapy, examining their ability to stimulate immune responses and induce tumor cell death. His work also explores the repurposing of existing vaccines, such as the trivalent MMR vaccine, as a cost-effective immunotherapy strategy.

Cannon's research extends to enhancing the effectiveness of these therapies through combination approaches. This includes investigating the synergy between oncolytic viruses and immune checkpoint blockade in models of hepatocellular carcinoma, as well as targeting tumor stroma to improve the resectability of pancreatic cancer treated with neoadjuvant virotherapy. A significant portion of his work involves understanding the immunological mechanisms underlying these treatments, specifically the role of dendritic cells in stimulating T cell-dependent antitumor immunity, as demonstrated in his NIH-funded project on Th17-inducing dendritic cell vaccines for ovarian cancer.

With a career marked by significant scholarly output, Cannon has published 157 papers, accumulating over 5,880 citations and an h-index of 44. He has secured federal funding for his research, including a $178,819 NIH/National Cancer Institute grant as PI for studying Th17-DC immunotherapy in ovarian cancer and a $693,302 NIH grant as Co-PI investigating the role of platelets in radiation-induced immune dysregulation. He actively collaborates with researchers at the University of Arkansas for Medical Sciences and other institutions.

Metrics

h-index: 44
Publications: 158
Citations: 5,905

Selected Publications

Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

DOI OpenAlex
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)

DOI OpenAlex
Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2025)

DOI OpenAlex
A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer (2025)

1 citation DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

4 citations DOI OpenAlex
Abstract 5004: Oncolytic Jurona-driven systemic and intratumoral immunotherapy combined with immune checkpoint blockade boost immune response and survival in hepatocellular carcinoma models (2024)

DOI OpenAlex
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockade (2023)

23 citations DOI OpenAlex
Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023)

DOI OpenAlex
Supplemental Figures 1-9 and Table S1 from Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking (2023)

DOI OpenAlex
Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy (2022)

6 citations DOI OpenAlex
Myxoma virus lacking the host range determinant M062 stimulates cGAS-dependent type 1 interferon response and unique transcriptomic changes in human monocytes/macrophages (2022)

14 citations DOI OpenAlex
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers (2022)

13 citations DOI OpenAlex
Abstract 3529: T-cell trafficking and extravasation is suppressed in distal tumors during gastrointestinal tract dysbiosis (2022)

DOI OpenAlex